Related Experiment Video
Updated: Jun 18, 2025

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022
Intraoperative Dexmedetomidine Improves the Outcome of Pediatric Cardiac Surgery: A One-Year Cohort Study
Fei Xu1, Lei Li2, Yanli Yang1
1Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, 100011 Beijing, China.
Insights
Intraoperative dexmedetomidine therapy significantly reduced mortality in children undergoing pediatric cardiac surgery. This finding offers a potential strategy to improve survival rates in these high-risk young patients.
Area of Science:
- Pediatric Cardiac Surgery
- Anesthesiology
- Critical Care Medicine
Background:
- Pediatric cardiac surgery carries substantial risks of mortality and morbidity.
- Investigating novel therapeutic strategies is crucial for improving outcomes in this vulnerable population.
Purpose of the Study:
- To evaluate the impact of intraoperative dexmedetomidine on survival rates in children after cardiac surgery.
- To determine if dexmedetomidine therapy can mitigate mortality risks associated with pediatric cardiac procedures.
Main Methods:
- Retrospective review of 1384 pediatric cardiac surgery patients.
- Comparison of outcomes between 889 patients receiving dexmedetomidine and 495 not receiving it.
- Multivariate logistic regression and propensity-score matching were employed to control for bias.
Main Results:
- Dexmedetomidine use was associated with significantly lower 30-day postoperative mortality (1.57% vs. 4.24%).
- One-year mortality was also reduced in the dexmedetomidine group (2.36% vs. 6.67%).
- No significant differences in cardiovascular complications were observed between the groups.
Conclusions:
- Intraoperative dexmedetomidine administration is linked to reduced 30-day and 1-year mortality in pediatric cardiac surgery patients.
- Dexmedetomidine may represent a valuable therapeutic option for enhancing survival after pediatric cardiac surgery.
Background:
Pediatric cardiac surgery is associated with a high risk of mortality and morbidity. The aim of this study was to determine if intraoperative dexmedetomidine therapy could improve survival after pediatric cardiac surgery.
Methods:
We conducted a retrospective review of 1384 consecutive children who underwent pediatric cardiac surgery. Amongst these, 889 received dexmedetomidine therapy and 495 did not. All children were followed for 1 year. Their in-hospital and long-term outcomes were compared by multivariate logistic regression to minimize bias, and propensity-score matched adjustment was used.
Results:
Children who received dexmedetomidine had lower mortality during the 30-day postoperative period compared to children who did not (1.57% vs. 4.24%; adjusted hazard ratio [HR]: 0.448; 95% confidence interval [CI]: 0.219-0.916, p = 0.028), as well as after 1 year (2.36% vs. 6.67%; adjusted [HR]: 0.487; 95% [CI]: 0.274-0.867, p = 0.014). The two groups showed no significant differences in cardiovascular complications.
Conclusions:
Dexmedetomidine administered intraoperatively reduced 30-day and 1-year mortality in children undergoing pediatric cardiac surgery.
More Related Videos
Related Concept Videos
Parenteral Anesthetics: Overview
Depolarizing Blockers: Pharmocokinetics
Stages of General Anesthesia
Inhalational Anesthetics: Overview
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

